CATEGORIES

Prof. Liu Xiaogang wins prestigious Royal Society of Chemistry Prize
BioSpectrum Asia

Prof. Liu Xiaogang wins prestigious Royal Society of Chemistry Prize

Professor Liu Xiaogang from the Department of Chemistry, National University of Singapore (NUS) has been named winner of the Royal Society of Chemistry’s Centenary Prize in recognition of brilliance in research and innovation.

time-read
1 min  |
BioSpectrum Asia July 2024
New blood test by Australian scientists tracks brain recovery after concussion
BioSpectrum Asia

New blood test by Australian scientists tracks brain recovery after concussion

A blood test can accurately detect the ongoing effects of sport-related concussion and help determine when it’s safe to return to the field, Australia's Monash University-led research has found.

time-read
1 min  |
BioSpectrum Asia July 2024
Australian Digital Health Agency appoints Dr Amandeep Hansra as new Chief Clinical Adviser (Medicine)
BioSpectrum Asia

Australian Digital Health Agency appoints Dr Amandeep Hansra as new Chief Clinical Adviser (Medicine)

The Australian Digital Health Agency, the Australian Government’s statutory agency responsible for My Health Record, Australia's digital prescriptions and health referral system, and other e-health programmes under the national digital health strategy, has announced the appointment of Dr Amandeep Hansra as its new Chief Clinical Adviser (Medicine).

time-read
1 min  |
BioSpectrum Asia July 2024
Macro Callouts for Healthcare Investing in Indial
BioSpectrum Asia

Macro Callouts for Healthcare Investing in Indial

India will have 1.2 billion people in the middleincome segment with over 42 per cent of the population in urban cities, by 2030. India’s healthcare and lifesciences market is estimated to reach 285 billion by 2028 implying a growth that is twice our GDP growth. These developments will lead to an estimated 30-35 billion in private capital investment getting allocated to the sector over the next 5 years.

time-read
4 mins  |
BioSpectrum Asia July 2024
Oxford University designs computer simulations to guide future vaccine trials
BioSpectrum Asia

Oxford University designs computer simulations to guide future vaccine trials

University of Oxford scientists are launching new computer simulations that will model how we can strengthen the world’s response to some of the viruses most likely to cause the next pandemic.

time-read
1 min  |
BioSpectrum Asia July 2024
WHO and Italian National Institute of Health sign MoU to improve care for healthy ageing
BioSpectrum Asia

WHO and Italian National Institute of Health sign MoU to improve care for healthy ageing

The World Health Organization (WHO) and the Dementia Observatory (Osservatorio Demenze) have signed a threeyear Memorandum of Understanding (MoU) to formalise a close collaboration and exchange aimed at improving care for healthy ageing

time-read
1 min  |
BioSpectrum Asia July 2024
Noul participates in malaria project initiated by US CDC
BioSpectrum Asia

Noul participates in malaria project initiated by US CDC

On-device AI healthcare startup in South Korea, Noul has announced that it will jointly participate in a malaria diagnosis project initiated by US Centers for Disease Control and Prevention (CDC) with the Kenya Medical Research Institute (KEMRI).

time-read
1 min  |
BioSpectrum Asia July 2024
EnGeneIC, Singapore Institute of Advanced Medicine forge partnership to revolutionise cancer treatment in Asia
BioSpectrum Asia

EnGeneIC, Singapore Institute of Advanced Medicine forge partnership to revolutionise cancer treatment in Asia

EnGeneIC, an Australiabased clinical-stage biopharmaceutical company pioneering the development of a First-in-Class targeted nano cell for cancer therapy, has announced strategic partnerships with Singapore Institute of Advanced Medicine Holdings (SAM) and Singapore Medical Incorporation (SMI).

time-read
1 min  |
BioSpectrum Asia July 2024
Singapore contributes S$24M to the WHO's inaugural investment round
BioSpectrum Asia

Singapore contributes S$24M to the WHO's inaugural investment round

At the World Health Organization’s (WHO) Strategic Roundtable on ‘All for Health, Health for All: the WHO Investment Case’ held in Geneva, Switzerland recently, Minister for Health Ong Ye Kung announced Singapore’s contribution of S$24 million to the WHO’s newly launched 2025/28 Investment Round.

time-read
1 min  |
BioSpectrum Asia July 2024
AbbVie inks deal worth $1.56B with China's FutureGen to develop IBD therapy
BioSpectrum Asia

AbbVie inks deal worth $1.56B with China's FutureGen to develop IBD therapy

US-based firm AbbVie and FutureGen Biopharmaceutical (Beijing) have announced a license agreement to develop FG-M701, a next-generation TL1A antibody for the treatment of inflammatory bowel disease (IBD) currently in preclinical development.

time-read
1 min  |
BioSpectrum Asia July 2024
Shionogi signs €400M deal with French firm Cilcare to address hearing loss
BioSpectrum Asia

Shionogi signs €400M deal with French firm Cilcare to address hearing loss

Japan-based Shionogi & Co. has entered into an option agreement with French firm Cilcare DEV SAS to acquire the exclusive license for the development, manufacturing and commercialization of CIL001 and/or CIL003, the hearing loss treatment drug candidates worldwide.

time-read
1 min  |
BioSpectrum Asia July 2024
Singapore launches child & maternal health, well-being strategy and action plan report
BioSpectrum Asia

Singapore launches child & maternal health, well-being strategy and action plan report

The Interagency Child and Maternal Health & Well-being (CAMH) Taskforce in Singapore has completed its Strategy and Action Plan and published its report.

time-read
1 min  |
BioSpectrum Asia July 2024
SS Innovations' Mantra surgical robotic system receives approval for use in Indonesia
BioSpectrum Asia

SS Innovations' Mantra surgical robotic system receives approval for use in Indonesia

Indian firm SS Innovations International, Inc. (SSII), a developer of innovative surgical robotic technologies dedicated to making world-class robotic surgery affordable and accessible to a global population, has announced that its SSi Mantra Surgical Robotic System has received regulatory approval from the Indonesian Ministry of Health for clinical use in the Republic of Indonesia.

time-read
1 min  |
BioSpectrum Asia July 2024
The Philippines- a preferred destination for medical education?
BioSpectrum Asia

The Philippines- a preferred destination for medical education?

The Philippines is revolutionising medical education by providing affordable and value-formoney learning options at a fraction of the cost. With yearly tuition prices ranging from 2,000 to 6,000, it offers an economically realistic option for ambitious professionals worldwide. Furthermore, its curriculum is matched with US standards, ensuring seamless integration into foreign jobs, particularly in North America. This is supported by a strong network of residency programmes in the United States that aggressively seek the expertise of Philippine medical graduates.

time-read
4 mins  |
BioSpectrum Asia July 2024
Why are strategic partnerships critical for life science innovation?
BioSpectrum Asia

Why are strategic partnerships critical for life science innovation?

Strategic alliances between startups and large companies will be more and more important as the life science sector develops because they will spur research and expedite the release of breakthrough treatments for patients. Innovation stays at the forefront of the industry thanks to the cooperative efforts of resource-rich businesses and nimble startups, which ultimately benefit patients and improve global health outcomes.

time-read
4 mins  |
BioSpectrum Asia July 2024
Pharma's Obsession With Obesity On Rise
BioSpectrum Asia

Pharma's Obsession With Obesity On Rise

Obesity is a rapidly growing global health issue. According to the World Obesity Federation, approximately one billion people worldwide will be affected by obesity by 2030. Obesity has become big pharma’'s latest obsession, with significant interest and investment in this space. Both big pharma and small startups are jumping into the race, investing billions in combating obesity. Let's delve deeper into what's driving the appetite for obesity drugs.

time-read
7 mins  |
BioSpectrum Asia July 2024
Eliminating Silent Killer Through Swift Actions
BioSpectrum Asia

Eliminating Silent Killer Through Swift Actions

Hepatitis continues to wreak havoc globally, with the latest World Health Organization WHO) report sounding alarms on viral hepatitis infections claiming 3,500 lives each day. The WHO estimates from 2022 reveal that 254 million people live with hepatitis B and 50 million with hepatitis C. The Asia Pacific APAC) region is at the epicentre of this crisis, hosting the top 7 highburden countries. Let's discuss the progress of the region towards achieving the 2030 targets for hepatitis elimination and identify what actions are needed to achieve these goals.

time-read
8 mins  |
BioSpectrum Asia July 2024
Innovation Takes Centre Stage in Paediatric healthcare
BioSpectrum Asia

Innovation Takes Centre Stage in Paediatric healthcare

Children represent approximately one-third of the world's population, with over 580 million in the East Asia and Pacific region alone Source: UNICEF). Historically underrepresented in healthcare care delivery and innovation, the landscape is evolving as governments and healthcare organisations in the region strive to address paediatric healthcare needs. Paediatric healthcare spans recommended immunisations before adulthood to developmental health, mental health, neonatal care and rare diseases, among others. Let's deep dive into the innovations enhancing children’s well being in the region.

time-read
8 mins  |
BioSpectrum Asia July 2024
Australia invests $1.89B for health and medical research transformation
BioSpectrum Asia

Australia invests $1.89B for health and medical research transformation

The government is investing in a once in a generation transformation of health and medical research in Australia.

time-read
1 min  |
June 2024
NZ suggests new way to prevent rheumatic heart disease progression
BioSpectrum Asia

NZ suggests new way to prevent rheumatic heart disease progression

A new way of delivering treatment to prevent rheumatic heart disease progression is significantly less painful than an almost 70-year-old existing treatment, a University of Otago-led study in New Zealand (NZ) has found.

time-read
1 min  |
June 2024
WHO prequalifies Takeda's dengue vaccine
BioSpectrum Asia

WHO prequalifies Takeda's dengue vaccine

A new vaccine for dengue has received prequalification from the World Health Organization (WHO).

time-read
1 min  |
June 2024
GIBF invests $10M in Israel's Nectin Therapeutics to advance ADCs
BioSpectrum Asia

GIBF invests $10M in Israel's Nectin Therapeutics to advance ADCs

Guangzhou-Israel Biotechnology Fund (GIBF) has invested $10 million in Nectin Therapeutics.

time-read
1 min  |
June 2024
HOYA Group to distribute AIassisted lesion detection device in US
BioSpectrum Asia

HOYA Group to distribute AIassisted lesion detection device in US

Japan-based HOYA Group Company, PENTAX of America, Inc. (PENTAX Medical, a division of HOYA Group) and MAGENTIQ-EYE, an artificial intelligence (AI)-based medical device company, have announced their intention to form a partnership in the field of AI in gastroenterology and to examine further collaboration and strategic partnerships.

time-read
1 min  |
June 2024
Saudi Arabia pledges $500M to protect children from polio
BioSpectrum Asia

Saudi Arabia pledges $500M to protect children from polio

At the first-ever World Economic Forum (WEF) Special Meeting hosted in Riyadh recently, the Kingdom of Saudi Arabia has pledged $500 million over the next five years to support the work of the Global Polio Eradication Initiative (GPEI).

time-read
1 min  |
June 2024
Scientists explore use of COVID-19 variant vaccine against other coronaviruses
BioSpectrum Asia

Scientists explore use of COVID-19 variant vaccine against other coronaviruses

An international consortium of researchers developing a vaccine against troublesome COVID-19 variants will receive additional CEPI funding to investigate whether it could also protect against other deadly coronaviruses.

time-read
1 min  |
June 2024
How Thai Biotech is Thriving with Innovations
BioSpectrum Asia

How Thai Biotech is Thriving with Innovations

Thailand's biotech industry is rapidly evolving, positioning itself as a key player in the ASEAN regions and the global biotechnology landscape. With a strategic focus on research and development, supportive government policies and a burgeoning ecosystem of startups and research institutions, Thailand is emerging as a hotspot for biotech innovation in Southeast Asia.

time-read
2 mins  |
June 2024
Why multi-use real estate is in demand for life sciences companies
BioSpectrum Asia

Why multi-use real estate is in demand for life sciences companies

India's Biocon, Enzene Biosciences, and Meteoric Biopharmacueticals, Japan's Daiichi Sankyo, and Singapore's Hummingbird Bioscience, have all recently sought to lease, acquire, and set up shop in a mixed-use space in the US. And for those companies who wish to enter or expand in the US market, New Jersey is a top choice due to its existing infrastructure, cultural connections, robust talent and location.

time-read
4 mins  |
June 2024
"The dialogue surrounding pharmaceutical gowning is experiencing significant transformation in 2024 & beyond"
BioSpectrum Asia

"The dialogue surrounding pharmaceutical gowning is experiencing significant transformation in 2024 & beyond"

Finland-based Lindström, a leading global provider of workwear, cleanroom workwear, and mat services, is making significant strides in its expansion efforts, particularly in key markets such as India, China, Vietnam, and Turkey.

time-read
5 mins  |
June 2024
"The rise of the middle class in Southeast Asia is driving the adoption of NGS"
BioSpectrum Asia

"The rise of the middle class in Southeast Asia is driving the adoption of NGS"

Taiwan-based ACT Genomics, a genomics company specialising in precision oncology with operations in Hong Kong, Taiwan, Japan, Singapore, Thailand, and the UK.

time-read
4 mins  |
June 2024
"There's a growing focus on developing novel ADCs tailored to address unmet medical needs"
BioSpectrum Asia

"There's a growing focus on developing novel ADCs tailored to address unmet medical needs"

Nona Biosciences, a subsidiary of Hong Kong-listed Harbour BioMed is an emerging leader in Antibody-drug conjugates (ADCs).

time-read
4 mins  |
June 2024